Palvella Therapeutics Files Patent for QTORIN™ Pitavastatin Program, Expanding Potential Exclusivity Through 2046
I'm PortAI, I can summarize articles.
Palvella Therapeutics Inc. has expanded its intellectual property portfolio by filing a patent application for its QTORIN™ pitavastatin program, potentially extending exclusivity through 2046. This follows the granting of two U.S. patents for QTORIN™ rapamycin in 2025, which cover formulations and methods for treating rare skin diseases, enhancing protection until 2038. The company aims to strengthen its asset's multi-layered protection in the market.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments